Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

被引：3119

作者：

Gopalakrishnan, V. ^{[1
,2
]}

Spencer, C. N. ^{[2
,3
]}

Nezi, L. ^{[3
]}

Reuben, A. ^{[1
]}

Andrews, M. C. ^{[1
]}

Karpinets, T. V. ^{[3
]}

Prieto, P. A. ^{[1
,20
]}

Vicente, D. ^{[1
]}

Hoffman, K. ^{[4
]}

Wei, S. C. ^{[5
]}

Cogdill, A. P. ^{[1
,5
]}

Zhao, L. ^{[3
]}

Hudgens, C. W. ^{[6
]}

Hutchinson, D. S. ^{[7
]}

Manzo, T. ^{[3
]}

de Macedo, M. Petaccia ^{[6
,21
]}

Cotechini, T. ^{[8
]}

Kumar, T. ^{[3
]}

Chen, W. S. ^{[9
]}

Reddy, S. M. ^{[10
]}

Sloane, R. Szczepaniak ^{[1
]}

Galloway-Pena, J. ^{[11
]}

Jiang, H. ^{[1
]}

Chen, P. L. ^{[9
,22
]}

Shpall, E. J. ^{[12
]}

Rezvani, K. ^{[12
]}

Alousi, A. M. ^{[12
]}

Chemaly, R. F. ^{[11
]}

Shelburne, S. ^{[3
,11
]}

Vence, L. M. ^{[5
]}

Okhuysen, P. C. ^{[11
]}

Jensen, V. B. ^{[13
]}

Swennes, A. G. ^{[7
]}

McAllister, F. ^{[14
]}

Sanchez, E. Marcelo Riquelme ^{[14
]}

Zhang, Y. ^{[14
]}

Le Chatelier, E. ^{[15
]}

Zitvogel, L. ^{[16
]}

Pons, N. ^{[15
]}

Austin-Breneman, J. L. ^{[1
,23
]}

Haydu, L. E. ^{[1
]}

Burton, E. M. ^{[1
]}

Gardner, J. M. ^{[1
]}

Sirmans, E. ^{[17
]}

Hu, J. ^{[18
]}

Lazar, A. J. ^{[6
,9
]}

Tsujikawa, T. ^{[8
]}

Diab, A. ^{[17
]}

Tawbi, H. ^{[17
]}

Glitza, I. C. ^{[17
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[2] Univ Texas Houston, Sch Publ Hlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA

[7] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA

[8] Oregon Hlth & Sci Univ, Dept Cell Dev & Cell Biol, Portland, OR 97239 USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA

[11] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA

[12] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Houston, TX 77030 USA

[13] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA

[15] Inst Natl Rech Agronom, Ctr Rech Jouy En Josas, F-78352 Jouy En Josas, France

[16] Inst Gustave Roussy, Ctr Invest Clin Biotherapie, F-94805 Villejuif, France

[17] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[19] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[20] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY 14642 USA

[21] AC Camargo Canc Ctr, Sao Paulo, Brazil

[22] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[23] Harvard Univ, Cambridge, MA 02138 USA

[24] MedImmune, Gaithersburg, MD 20878 USA

来源：

SCIENCE | 2018年 / 359卷 / 6371期

关键词：

INTESTINAL MICROBIOTA; CTLA-4; BLOCKADE; PD-1; CANCER; THERAPY; SENSITIVITY; MECHANISMS; IPILIMUMAB; DIVERSITY; NIVOLUMAB;

D O I：

10.1126/science.aan4236

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (n = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P < 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01) in responding patients. Metagenomic studies revealed functional differences in gut bacteria in responders, including enrichment of anabolic pathways. Immune profiling suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients. Together, these data have important implications for the treatment of melanoma patients with immune checkpoint inhibitors.

引用

页码：97 / 103

页数：7

共 50 条

[1] Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma
Zheng, Yi
Wang, Tingting
Tu, Xiaoxuan
Huang, Yun
Zhang, Hangyu
Tang, Di
Jiang, Weiqin
Cai, Shunfeng
Zhao, Peng
Song, Ruixue
Li, Peilu
Qin, Nan
Fang, Weijia
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[2] Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response
Uzelac, Matthew
Li, Wei Tse
Li, Yuxiang
Ongkeko, Weg M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
Mao, Jinzhu
Wang, Dongxu
Long, Junyu
Yang, Xu
Lin, Jianzhen
Song, Yiwei
Xie, Fucun
Xun, Ziyu
Wang, Yanyu
Wang, Yunchao
Li, Yiran
Sun, Huishan
Xue, Jingnan
Song, Yang
Zuo, Bangyou
Zhang, Junwei
Bian, Jin
Zhang, Ting
Yang, Xiaobo
Zhang, Lei
Sang, Xinting
Zhao, Haitao
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (12)
[4] Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome
Gopalakrishnan, Vancheswaran
Spencer, Christine
Reuben, Alexandre
Prieto, Peter
Vicente, Diego
Karpinets, Tatiana V.
Hudgens, Courtney W.
Hutchinson, Diane S.
Tetzlaff, Michael
Lazar, Alexander
Davies, Michael A.
Gershenwald, Jeffrey E.
Jenq, Robert
Hwu, Patrick
Sharma, Padmanee
Allison, James
Futreal, Andrew
Ajami, Nadim
Petrosino, Joseph
Daniel-MacDougall, Carrie
Wargo, Jennifer A.
CANCER RESEARCH, 2017, 77
[5] The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
Peng, Zhi
Cheng, Siyuan
Kou, Yan
Wang, Ziqi
Jin, Rong
Hu, Han
Zhang, Xiaotian
Gong, Ji-fang
Li, Jian
Lu, Ming
Wang, Xicheng
Zhou, Jun
Lu, ZhiHao
Zhang, Quan
Tzeng, David T. W.
Bi, Dongtao
Tan, Yan
Shen, Lin
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (10) : 1251 - 1261
[6] The gut microbiome is associated with clinical responses to anti-PD-1 immunotherapy in gastrointestinal cancer patients in China
Peng, Zhi
Cheng, Siyuan
Zhang, Quan
Kou, Yan
Wang, Ziqi
Jin, Rong
Hu, Han
Zhang, Xiaotian
Gong, Jifang
Li, Jian
Lu, Ming
Wang, Xicheng
Zhou, Jun
Lu, Zhihao
Bi, Dongtao
Tan, Yan
Shen, Lin
CANCER RESEARCH, 2020, 80 (16)
[7] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Subrahmanyam, Priyanka
Dong, Zhiwan
Gusenleitner, Daniel
Giobbie-Hurder, Anita
Severgnini, Mariano
Zhou, Jun
Manos, Michael
Maecker, Holden
Hodi, F. Stephen
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[8] Circulating tumor DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients
Ashida, A.
Sakaizawa, K.
Uhara, H.
Okuyama, R.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S291 - S291
[9] Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients
Ashida, Atsuko
Sakaizawa, Kaori
Uhara, Hisashi
Okuyama, Ryuhei
ACTA DERMATO-VENEREOLOGICA, 2017, 97 (10) : 1212 - 1218
[10] Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti-PD-1 Therapy
Szostak, Natalia
Handschuh, Luiza
Samelak-Czajka, Anna
Tomela, Katarzyna
Pietrzak, Bernadeta
Schmidt, Marcin
Galus, Lukasz
Mackiewicz, Jacek
Mackiewicz, Andrzej
Kozlowski, Piotr
Philips, Anna
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (04) : 427 - 439

← 1 2 3 4 5 →